特立帕肽(Sawai Pharmaceutical)(Teriparatide Acetata(Sawai Pharmaceutical)) - 药物靶点：PTH1R_在研适应症：骨质疏松症_专利_临床

概要

基本信息

药物类型

合成多肽

别名-

靶点

PTH1R

作用机制

PTH1R激动剂(甲状旁腺激素受体激动剂)

治疗领域

内分泌与代谢疾病皮肤和肌肉骨骼疾病

在研适应症

骨质疏松症

非在研适应症-

原研机构

Sawai Pharmaceutical Co., Ltd.

在研机构

Sawai Pharmaceutical Co., Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (2022-06-17),

骨质疏松症

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

7

项与特立帕肽(Sawai Pharmaceutical) 相关的临床试验

NCT03133195

/ Completed临床3期IIT

A Phase III, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Teriparatide on Bone Union in Unstable Intertrochanteric Fracture Patients Treated With Proximal Femoral Nail Antirotation (PFNA)

Phase III, prospective, randomized, parallel, double blind, placebo-controlled study to determine whether Teriparatide can accelerate bone healing in unstable intertrochanteric fracture patients treated with Proximal Femoral Nail Antirotation (PFNA) assessed by radiographic and clinical outcomes.

开始日期2017-05-17

申办/合作机构

King Chulalongkorn Memorial Hospital

JPRN-UMIN000023344

/ CompletedN/AIIT

The efficacy of teriparatide for the bone strength of patients suffered proximal femoral fracture, evaluated by computed tomographic finite element analysis - The efficacy of teriparatide for the bone strength of patients suffered proximal femoral fracture, evaluated by computed tomographic finite element analysis

开始日期2016-10-28

申办/合作机构-

JPRN-UMIN000022598

/ SuspendedN/AIIT

Study on inhibitory effect of teriparatide in knee osteoarthritis - Inhibitory effect of teriparatide in knee osteoarthritis

开始日期2016-08-01

申办/合作机构-

100 项与特立帕肽(Sawai Pharmaceutical) 相关的临床结果

登录后查看更多信息

100 项与特立帕肽(Sawai Pharmaceutical) 相关的转化医学

登录后查看更多信息

100 项与特立帕肽(Sawai Pharmaceutical) 相关的专利（医药）

登录后查看更多信息

1

项与特立帕肽(Sawai Pharmaceutical) 相关的文献（医药）

Bone Research

Differential bone and vessel type formation at superior and dura periosteum during cranial bone defect repair

Article

作者: Xing, Xiaojie ; Nuzzle, Mark ; Zhai, Yuankun ; Zhang, Xinping ; Zhou, Zhuang

AbstractThe cranial mesenchyme, originating from both neural crest and mesoderm, imparts remarkable regional specificity and complexity to postnatal calvarial tissue. While the distinct embryonic origins of the superior and dura periosteum of the cranial parietal bone have been described, the extent of their respective contributions to bone and vessel formation during adult bone defect repair remains superficially explored. Utilizing transgenic mouse models in conjunction with high-resolution multiphoton laser scanning microscopy (MPLSM), we have separately evaluated bone and vessel formation in the superior and dura periosteum before and after injury, as well as following intermittent treatment of recombinant peptide of human parathyroid hormone (rhPTH), Teriparatide. Our results show that new bone formation along the dura surface is three times greater than that along the superior periosteal surface following injury, regardless of Teriparatide treatment. Targeted deletion of PTH receptor PTH1R via SMA-CreER and Col 1a (2.3)-CreER results in selective reduction of bone formation, suggesting different progenitor cell pools in the adult superior and dura periosteum. Consistently, analyses of microvasculature show higher vessel density and better organized arterial-venous vessel network associated with a 10-fold more osteoblast clusters at dura periosteum as compared to superior periosteum. Intermittent rhPTH treatment further enhances the arterial vessel ratio at dura periosteum and type H vessel formation in cortical bone marrow space. Taken together, our study demonstrates a site-dependent coordinated osteogenic and angiogenic response, which is determined by regional osteogenic progenitor pool as well as the coupling blood vessel network at the site of cranial defect repair.

100 项与特立帕肽(Sawai Pharmaceutical) 相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
骨质疏松症	日本	Sawai Pharmaceutical Co., Ltd.	2022-06-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


WCO_IOF_ESCEO2023	N/A	骨质疏松性骨折	415	Teriparatide	憲膚鏇廠襯鑰膚繭醖積(膚鹹顧壓襯膚夢艱窪簾) = 製願襯願廠憲願構製觸網餘獵鏇積鹽鹹廠壓簾 (遞網廠鏇膚製獵鏇遞築 )	积极	2023-05-04
				Placebo	憲膚鏇廠襯鑰膚繭醖積(膚鹹顧壓襯膚夢艱窪簾) = 壓艱築醖鹹襯遞觸憲積網餘獵鏇積鹽鹹廠壓簾 (遞網廠鏇膚製獵鏇遞築 )
WCO_IOF_ESCEO2023	N/A	背痛 \| 脊柱骨折	200	Teriparatide 20 g	夢廠選觸願醖顧夢築築(壓製繭遞膚鹽繭觸壓繭) = Wedge type 蓋淵壓製餘淵餘膚艱蓋 (膚衊觸窪窪淵淵壓廠淵 )	积极	2023-05-04
ACTIVE (ENDO2020)	N/A	-	750	Abaloparatide	繭顧鏇觸衊膚網網鹽積(觸壓製糧選淵願觸衊鬱) = 襯簾選遞鑰積餘憲網餘襯觸遞憲壓遞範積鹽糧 (鑰窪獵簾衊壓積簾餘鑰 )	积极	2020-05-08
				Teriparatide	繭顧鏇觸衊膚網網鹽積(觸壓製糧選淵願觸衊鬱) = 鑰構膚範鹽願齋壓範製襯觸遞憲壓遞範積鹽糧 (鑰窪獵簾衊壓積簾餘鑰 )